Document Detail


Ustekinumab.
MedLine Citation:
PMID:  20069753     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ustekinumab is an anti-IL12/23 IgG1 kappa human monoclonal antibody currently undergoing US Food and Drug Administration review for use as a psoriasis treatment. The candidate has also been evaluated in Phase 2 studies as a treatment for psoriatic arthritis, Crohn disease and multiple sclerosis.In large clinical trials, ustekinumab has proven effective for treating moderate to severe plaque psoriasis. Although long-term follow-up studies are needed to address safety concerns, the hopes are high for psoriasis treatment. Ustekinumab has recently been approved for marketing in Canada and Europe.
Authors:
Oya Cingoz
Related Documents :
18341163 - Fast eating syndrome: a case report.
7756873 - U.s. food and drug administration monitoring of lead in domestic and imported ceramic d...
3930353 - Lysinoalanine: absence of mutagenic response in the salmonella/mammalian-microsome muta...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  mAbs     Volume:  1     ISSN:  1942-0870     ISO Abbreviation:  MAbs     Publication Date:    2009 May-Jun
Date Detail:
Created Date:  2010-01-13     Completed Date:  2010-06-10     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  101479829     Medline TA:  MAbs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  216-21     Citation Subset:  IM    
Affiliation:
Department of Molecular Biology and Microbiology; Tufts University School of Medicine; Boston, MA 02111, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Arthritis, Psoriatic / drug therapy*,  immunology
Canada
Clinical Trials as Topic
Crohn Disease / drug therapy*,  immunology
Drug Approval
Europe
Humans
I-kappa B Proteins / immunology
NF-kappa B / antagonists & inhibitors
United States
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/I-kappa B Proteins; 0/NF-kappa B; 139874-52-5/NF-kappaB inhibitor alpha; FU77B4U5Z0/ustekinumab
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Plants and pigeonholes: classification as a practice in American ecology.
Next Document:  Antibody drug-conjugates targeting the tumor vasculature: Current and future developments.